Ishara Investments LP Acquires New Holdings in Lexicon Pharmaceuticals, Inc. $LXRX

Posted by Stanley Muller on Jun 18th, 2026

Ishara Investments LP acquired a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 880,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,012,000. Lexicon Pharmaceuticals accounts for about 1.2% of Ishara Investments LP’s investment portfolio, making the stock its 29th largest holding. Ishara Investments LP owned about 0.24% of Lexicon Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. ExodusPoint Capital Management LP bought a new position in Lexicon Pharmaceuticals during the fourth quarter valued at approximately $309,000. Graham Capital Management L.P. bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth approximately $126,000. OMERS ADMINISTRATION Corp bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth approximately $315,000. Barclays PLC raised its position in Lexicon Pharmaceuticals by 511.2% in the fourth quarter. Barclays PLC now owns 194,743 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 162,881 shares during the period. Finally, Security National Bank of Sioux City Iowa IA bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth approximately $31,000. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Up 4.6%

LXRX opened at $2.04 on Thursday. The company has a current ratio of 18.80, a quick ratio of 18.77 and a debt-to-equity ratio of 0.24. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.70 and a 1-year high of $2.53. The company has a market capitalization of $906.16 million, a PE ratio of -29.14 and a beta of 1.07. The firm’s 50 day simple moving average is $1.93 and its two-hundred day simple moving average is $1.59.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $0.00 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.04. The business had revenue of $21.10 million for the quarter, compared to the consensus estimate of $9.79 million. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%. As a group, equities analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.17 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on LXRX shares. Citigroup increased their price target on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a research report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, March 23rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $4.55.

Get Our Latest Stock Report on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Profile

(Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.